Market Research Logo

Generic Drugs Market in Japan 2015-2019

Generic Drugs Market in Japan 2015-2019

About Generic Drugs

A generic drug is a duplicate of brand-name drugs and has the same dosage form, active ingredient(s), potency, route of administration, quality, and intended use as that of branded drugs. Generic drugs enter the market once the patent protection of the original developer expires. Generally, the cost of generic drugs is 50-70 percent lower than that of their brand-name counterparts, while meeting the very same standards of safety, quality, and efficacy as the innovator drugs. Generic drugs help the manufacturer by eliminating the need to develop and market a new drug. As the patent approaches expiration, manufacturers can apply to the FDA for approval to manufacture and sell generic versions of the drug. Generic drugs are equal to and within the bioequivalence range of branded drugs.

TechNavio's analysts forecast the Generic Drugs market in Japan to grow at a CAGR of 8.16 percent over the period 2014-2019.

Covered in this Report

The Generic Drugs market in Japan can be divided into three segments: Generic Prescription Medicines, Super Generics, and Biosimilars. This report covers the present scenario and the growth prospects of the Generic Drugs market in Japan for the period 2015–2019. To calculate the market size, the report considers the revenue generated from the following segments:

  • Generic Prescription Medicines
  • Super Generics
  • Biosimilars
TechNavio's report, the Generic Drugs market in Japan 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape of the Generic Drugs market in Japan and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Vendors
  • Meiji Seika Pharma
  • Nichi-Iko Pharmaceutical
  • Nipro Pharma
  • Sawai Pharmaceuticals
  • Teva Pharmaceutical Industries
  • Towa Pharmaceutical
Other Prominent Vendors
  • Actavis
  • Daiichi Sankyo
  • Daito Pharmaceutical
  • Eisai
  • Fuji Pharma
  • GlaxoSmithKline
  • Hikari Pharmaceutical
  • Hospira
  • Mylan
  • Nihon Generic
  • Nippon Chemipher
  • Nippon Kayaku
  • Nissin Pharmaceutical
  • Ohara Pharmaceutical
  • Pfizer
  • Sandoz
  • Taiyo Yakuhin
  • Takeda Pharmaceutical
  • Zensei Pharmaceutical Industries
Market Driver
  • Increase in Number of Patent Expiries
  • For a full, detailed list, view our report.
Market Challenge
  • Intense Competition among Vendors
  • For a full, detailed list, view our report
Market Trend
  • Increase in M&A
  • For a full, detailed list, view our report
Key Questions Answered in this Report
  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

TechNavio Announces the Publication of its Research Report – Generic Drugs Market in Japan 2015-2019

TechNavio recognizes the following companies as the key players in the Generic Drugs Market in Japan: Meiji Seika Pharma Co. Ltd., Nichi-Iko Pharmaceutical Co. Ltd., Nipro Pharma Corp., Sawai Pharmaceuticals Co. Ltd., Teva Pharmaceutical Industries Ltd. and Towa Pharmaceutical Co. Ltd.

Other Prominent Vendors in the market are: Actavis, Daiichi Sankyo, Daito Pharmaceutical, Eisai, Fuji Pharma, GlaxoSmithKline, Hikari Pharmaceutical, Hospira, Mylan, Nihon Generic, Nippon Chemipher, Nippon Kayaku, Nissin Pharmaceutical, Ohara Pharmaceutical, Pfizer, Sandoz, Taiyo Yakuhin, Takeda Pharmaceutical and Zensei Pharmaceutical Industries.

Commenting on the report, an analyst from TechNavio’s team said: “Increased initiatives by government and healthcare service providers are one of the major trends emerging in the market. Doctors and pharmacists are encouraged to use generics and reassure patients of their quality and efficacy.”

According to the report, the patents of many first-generation approved biopharmaceuticals are set to expire within the forecast period, leading to competition from generic drugs. As a result of the economic crisis, the development of new drugs has been hindered. Major companies in the market have allocated minimal funds for the R&D of innovative drugs. This has led to the drying up of pipeline drugs, paving the way for the Generic Drugs market.

Further, the report states that intense competition among vendors is one of the primary challenges, leading to a decrease in profit margins and an increase in pricing pressure. As a result of the intense competition, leading vendors are currently operating on low-profit margins with severe pressure on pricing strategies.

Companies Mentioned

Meiji Seika Pharma, Nichi-Iko Pharmaceutical, Nipro Pharma, Sawai Pharmaceuticals, Teva Pharmaceutical Industries, Towa Pharmaceutical, Actavis, Daiichi Sankyo, Daito Pharmaceutical, Eisai, Fuji Pharma, GlaxoSmithKline, Hikari Pharmaceutical,Hospira, Mylan, Nihon Generic, Nippon Chemipher, Nippon Kayaku, Nissin Pharmaceutical, Ohara Pharmaceutical, Pfizer, Sandoz, Taiyo Yakuhin, Takeda Pharmaceutical, Zensei Pharmaceutical Industries

  • Executive Summary
  • List of Abbreviations
  • Scope of the Report
    • Market Overview
    • Product Offerings
  • Market Research Methodology
    • Market Research Process
    • Research Methodology
      • Table Market Research Methodology
  • Introduction
  • Overview of Japan
    • Table Overview of Japan
  • Approval Pathway of Generic Drugs in Japan
    • Table Main Data Required for Approval of Generic Drugs
    • Master File Scheme for Active Ingredients
    • Equivalency Review
    • Conformity Audit
  • Market Landscape
    • Market Overview
      • Table Overview of Generic Drugs Market in Japan
    • Market Size and Forecast
      • Table Generic Drugs Market in Japan 2014-2019 (US$ billion)
      • Table Parameters to Promote Use of Generic Drugs
      • Table Share of Generic Drugs Market in Japan 2014
      • Table Share of Generic Drugs Market in Japan 2019
      • Table Share of Generic Drugs Market in Japan 2014 and 2019 (US$ billion)
    • Five Forces Analysis
  • Market Segmentation by Product Category
    • Table Segmentation of Generic Drugs Market in Japan by Product Category
  • Market Segmentation by Therapeutic Application
    • Table Segmentation of Generic Drugs Market in Japan by Therapeutic Application
  • Buying Criteria
  • Market Growth Drivers
    • Table Expiry of Patent of Branded Drugs in Japan
    • Table Medical Costs in Japan (thousand billion)
    • Table Price Difference of Atorvastatin between Originator and Generic in Japan (US$)
    • Table Trends of Elderly Population (percent)
  • Drivers and their Impact
  • Market Challenges
    • Table Reviews Conducted for Generic Drugs and Others 2008-2012
    • Table Comparison between Applications Filed and Approved in Japan 2008-2012
  • Impact of Drivers and Challenges
  • Market Trends
  • Trends and their Impact
  • Vendor Landscape
    • Competitive Scenario
      • Key News
      • Mergers and Acquisitions
    • Market Share Analysis 2014
    • Other Prominent Vendors
  • Key Vendor Analysis
    • Meiji Seika Pharma
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Meiji Seika Pharma: Business Segmentation
      • Key Product Pipeline
        • Table Meiji Seika Pharma: Key Product Pipeline
      • Geographical Presence
        • Table Meiji Seika Pharma: Geographical Presence
      • SWOT Analysis
    • Nichi-Iko Pharmaceutical
      • Key Facts
      • Business Overview
      • Business Strategy
      • Recent Developments
      • SWOT Analysis
    • Nipro Pharma
      • Key Facts
      • Business Overview
      • Key Product Categories
        • Table Nipro Pharma: Key Product Categories
      • Recent Developments
      • SWOT Analysis
    • Sawai
      • Key Facts
      • Business Overview
      • Product Segmentation by Revenue 2014
        • Table Sawai: Product Segmentation by Revenue 2014
      • Geographical Presence
        • Table Sawai: Geographical Presence
      • Recent Developments
      • SWOT Analysis
    • Teva Pharmaceutical
      • Key Facts
      • Business Overview
      • Business Segmentation
        • Table Teva: Business Segmentation
      • Revenue by Business Segmentation
        • Table Teva: Revenue by Business Segmentation 2013
      • Revenue Comparison 2012 and 2013
        • Table Teva: Revenue by Business Segmentation 2012 and 2013 (US$ million)
      • Revenue Segmentation by Geography
        • Table Teva: Revenue by Geographical Segmentation 2013
      • Business Strategy
      • Key Developments
      • SWOT Analysis
    • Towa
      • Key Facts
      • Business Overview
      • Product Portfolio
        • Table Towa: Product Portfolio
      • Geographical Presence
        • Table Towa: Geographical Presence
      • SWOT Analysis
  • Other Reports in this Series

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report